Replies to post #150053 on NorthWest Biotherapeutics Inc (NWBO)

[GoodGuyBill]

Because they have reason to believe the trial will not succeed. They need money to keep the company operating for the combo trial.

sentiment,


you are focussed on other investors being able getting in this new offer.
All nice but.
What are your thoughts on why another approx 12 million from this offer when they just raised 12 million a month ago? What is all the money for if they downsized overhead to 1,5 million p/m and stated that Cognate/Advent will from now on only charge per patient? What is the 19 million (after paying Cognate/Adv. the 5 million for?) certainly if one expects a read out any moment what the SP would rise... then why another 12 million? Other than the payment for another year of silence?

Thanks for answering

[sentiment_stocks]

What are your thoughts on why another approx 12 million from this offer when they just raised 12 million a month ago?

They spent some of that $12 million dating back to October when the first of those deals was done (listed in the 10Q from November). I have no idea what their monthly outlay is at this point - so I can only guess at that (which is probably pretty useless). I know they had to pay Cognate some amount of cash towards the debt - $5 or 7 million? I can't remember without looking it up.

So my thoughts are either:

They need more cash than what the $12 million brought in to see them to the plan - whatever the plan is, lol.

Or

They are offering this financing to ensure they've very publicly made their shareholders aware that they have the opportunity to do the same as Cognate.

Or

They want to increase the vote count with longs.

What is all the money for if they downsized overhead to 1,5 million p/m and stated that Cognate/Advent will from now on only charge per patient?

We don't know what the research and development costs are going towards. Of course it's highly unlikely it's going towards making any vaccines - except for possibly a few for some small number of patients in the UK. But we don't really don't know how the funding is being spent, or why they want to bring in up to an additional $12 million.

Looks like at least the "interim blinded data" is likely not coming by December 29 (the last day of this financing), so perhaps the possible delay on that is why?